Drug intelligence / Profile preview

OL TL1

Development stage: Preclinical
Lead developer: Oleolive
Modality: Small Molecules

Overview

OL TL1 is a small molecule therapeutic developed by Oleolive that targets TROY (Tumor Necrosis Factor Receptor Superfamily Member 19). It is specifically designed for the treatment of glioblastoma (GBM). The drug's mechanism of action involves targeting TROY to sensitize GBM tumors to standard-of-care treatments, including radiotherapy and the chemotherapy agent temozolomide. By modulating TROY signaling, OL TL1 aims to overcome treatment resistance in aggressive brain tumors. It is currently in the IND-enabling stage of development.

Targets

TNFRSF19 (Tumor necrosis factor receptor superfamily member 19)

Beyond the preview

Go deeper on OL TL1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OL TL1.

Explore the full profile